Business Context and Reporting Period
This Form 8-K is a current report filed by Aerpio Pharmaceuticals, Inc. on March 22, 2019. The filing addresses a corporate governance event regarding the departure of a senior officer. Note: The request metadata references "Whitehawk Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Aerpio Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the resignation of Stephen Pakola, M.D., as Chief Medical Officer. Dr. Pakola notified the company of his intention to resign effective April 17, 2019. The filing explicitly states that the resignation did not result from any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or discussion of general business risks. The only contingency noted is the upcoming vacancy of the Chief Medical Officer role effective April 17, 2019.
Investor Verification Checklist
- Verify the appointment of a successor Chief Medical Officer to replace Dr. Pakola.
- Confirm the effective date of the resignation (April 17, 2019) and any interim leadership arrangements.
- Review subsequent filings for any impact on clinical trial timelines or regulatory interactions due to the leadership change.